Patents by Inventor Edward R. DAMIANO
Edward R. DAMIANO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957876Abstract: An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.Type: GrantFiled: March 25, 2021Date of Patent: April 16, 2024Assignee: BETA BIONICS, INC.Inventors: Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
-
Patent number: 11941392Abstract: An ambulatory medical device can detect a device condition and determine if the device condition satisfies a set of normal operating parameters. If the normal operating parameters are not satisfied, the ambulatory medical device can determine if the device condition stratifies a set of minimum operating parameters. If the minimum operating parameters are satisfied, the ambulatory medical device can maintain a delivery of therapy to a subject and generate an alert based on the device condition.Type: GrantFiled: September 27, 2021Date of Patent: March 26, 2024Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, David Chi-Wai Lim
-
Publication number: 20240050652Abstract: A multi-medicament infusion system (10) for preventing the mischanneling of medicaments may include an infusion pump (12), medicament reservoirs (16A,16B), a multi-channel lumen (18), and an infusion set (20). The medicament reservoirs may be sized and shaped differently such that the medicament reservoirs can only be inserted into the infusion pump in a unique configuration. The multi-channel lumen may include connectors that mate to corresponding connectors on the infusion pump and the infusion set only in a unique configuration. Because the various parts of the multi-infusion system may only be connected in the unique configuration, the expected medicaments may be administered appropriately and channeled to the correct infusion sites.Type: ApplicationFiled: June 28, 2023Publication date: February 15, 2024Inventors: Edward R. Damiano, Kirk D. Ramey, Firas H. El-Khatib
-
Publication number: 20240024578Abstract: A glucose level control system may be configured to determine that certain status information fails to satisfy at least one of a plurality of safety thresholds. The system may receive status information, which may include device information pertaining to a condition of the ambulatory medicament device and/or subject information pertaining to a condition of a subject. The system can determine that the status information fails to satisfy the safety threshold(s). In response to determining that the status information fails to satisfy the at least one of a plurality of safety thresholds, the system can automatically execute a distress action. Example safety thresholds include a glucose level of a subject being less than a minimum threshold, a glucose level of a subject being greater than a maximum threshold, a movement of the subject being less than a minimum movement threshold for a threshold amount of time, and/or other safety thresholds.Type: ApplicationFiled: July 18, 2023Publication date: January 25, 2024Inventors: Himanshu Patel, Michael J. Rosinko, Firasd H. El-Khatib, Edward R. Damiano
-
Publication number: 20230381413Abstract: A glucose level control system may be configured to adapt a time-segmented basal dose. The glucose level control system may determine the first basal dose based at least in part on a user-specified basal dose and/or total daily dose value. The first basal dose may also be based on a basal dose received from the memory of the glucose level control system or from a remote storage device. The first basal dose may be administered during a first time period. The glucose level control system may adapt the first basal dose to a second basal dose for a second therapy period. The glucose level control system may adapt the second basal dose based on a difference between a predicted and measured glucose level.Type: ApplicationFiled: May 24, 2023Publication date: November 30, 2023Inventors: Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
-
Patent number: 11803367Abstract: Systems and methods are disclosed herein for monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device. The ambulatory medical device can have a touchscreen display user interface to receive input signals from a user and display alarm conditions associated with the status of an ambulatory medical device or health condition of a subject. The disclosed methods and systems can determine whether status information received from a monitoring system interface satisfies an alarm condition for the ambulatory medicament device or for the subject. If the status information satisfies an alarm condition, the touchscreen user interface can display one or more alarm status indicators corresponding to the alarm condition. The user can activate a therapy change interface on the touchscreen display and modify a control parameter of the ambulatory medical device that controls the therapy delivery to the subject.Type: GrantFiled: September 27, 2021Date of Patent: October 31, 2023Assignee: Beta Bionics, Inc.Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Justin P. Brown, Bryan Dale Knodel, Himanshu Patel
-
Publication number: 20230337949Abstract: A glucose level control system may be configured to determine that certain status information fails to satisfy at least one of a plurality of safety thresholds. The system may receive status information, which may include device information pertaining to a condition of the ambulatory medicament device and/or subject information pertaining to a condition of a subject. The system can determine that the status information fails to satisfy the safety threshold(s). In response to determining that the status information fails to satisfy the at least one of a plurality of safety thresholds, the system can automatically execute a distress action. Example safety thresholds include a glucose level of a subject being less than a minimum threshold, a glucose level of a subject being greater than a maximum threshold, a movement of the subject being less than a minimum movement threshold for a threshold amount of time, and/or other safety thresholds.Type: ApplicationFiled: April 19, 2023Publication date: October 26, 2023Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
-
Publication number: 20230338643Abstract: A glucose level control system can intermittently receive alarm data corresponding to instances where an alarm was triggered and receive a request for the remote support system to contact the user. The system can transmit the request to the remote support system and determine that at least one of a plurality of support system criteria are satisfied. The control system can automatically identify a category of concern related to the request and generate a report of usage based on the category of concern and on the alarm data. The control system may transmit the report of usage to a remote electronic device and determine a support resource configured to receive the report of usage associated with the glucose level control system. The control system can generate a connection alert that is configured to request contact with a support request interface operatively coupled to the ambulatory medicament pump.Type: ApplicationFiled: April 18, 2023Publication date: October 26, 2023Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
-
Patent number: 11771821Abstract: Multi-medicament infusion systems prevent cross-channeling of medicaments. A system may include one or more of an infusion pump, medicament reservoirs, a multi-channel fluid conduit, and an infusion set. Medicament reservoirs and/or collars may be sized and shaped differently such that the medicament reservoirs can only be inserted into the system under selected configurations.Type: GrantFiled: December 3, 2020Date of Patent: October 3, 2023Assignees: Trustees of Boston University, Beta Bionics, Inc.Inventors: Edward R. Damiano, Rajendranath Selagamsetty, Firas H. El-Khatib, Bryan D. Knodel, Raymond A. Carr
-
Patent number: 11768676Abstract: Systems and methods are disclosed herein for switching control of an ambulatory medical device from an application executing on the ambulatory medical device to a safe version or a new version of the application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device can maintain copies of a safe version and a new version of the application. The disclosed systems and methods can execute the new version, while the prior version of the application continues to execute, determine whether a minimum set of operating conditions are satisfied by the new version, and switch control of the ambulatory medical device from the prior version to the new version. The systems and methods can also automatically revert to the safe version of the application case the current version is malfunctioning without interrupting therapy provided to the subject.Type: GrantFiled: September 17, 2021Date of Patent: September 26, 2023Assignee: Beta Bionics, Inc.Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Himanshu Patel, John R. Costik, Justin P. Brown, Bryan Dale Knodel
-
Patent number: 11766518Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.Type: GrantFiled: March 26, 2021Date of Patent: September 26, 2023Assignee: BETA BIONICS, INC.Inventors: Firas H. El-Khatib, Edward R. Damiano
-
Publication number: 20230293815Abstract: A glucose level control system can access a manufacturer specification that is configured to establish a minimum operating parameter of an associated ambulatory medicament pump. The control system can determine, via a pump monitoring system, a functional state of at least one of a plurality of pump components of the ambulatory medicament pump. The control system can determine, in response to determining the functional state of the at least one of the plurality of pump components, that the ambulatory medicament pump fails to meet the manufacturer specification and automatically generate a replacement alert that is configured to indicate that the ambulatory medicament pump may need to be replaced. The control system can transmit a request to a remote electronic device for a replacement ambulatory medicament pump.Type: ApplicationFiled: March 15, 2023Publication date: September 21, 2023Applicant: BETA BIONICS, INC.Inventors: Michael J. Rosinko, Himanshu Pate, Edward R. Damiano, Firas H. El-Khatib
-
Publication number: 20230298724Abstract: A medical device, such as an ambulatory medicament pump or associate control system, can receive a use state comprising user interactions with the glucose level control system. The device can determine that the use state satisfies at least one of a plurality of user interaction criteria. The plurality of user interaction criteria can include a variety of various interaction criteria. In response to determining that the use state satisfies the at least one of the plurality of user interaction criteria, the system can automatically generate the user alert comprising a link to training content. The link can direct a user to the training content in response to user interaction with the link.Type: ApplicationFiled: March 17, 2023Publication date: September 21, 2023Applicant: Beta Bionics, Inc.Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
-
Patent number: 11744945Abstract: A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.Type: GrantFiled: November 16, 2020Date of Patent: September 5, 2023Assignees: Trustees of Boston University, The General Hospital CorporationInventors: Firas H. El-Khatib, Edward R. Damiano, Steven J. Russell
-
Patent number: 11744947Abstract: A blood glucose control system is configured to modify therapy provide to a subject and determine whether the modified therapy results in a statistically significant improvement in glycemic control. The system obtains glycemic control information resulting from delivery of first therapy using a first value of a control parameter and determines a first effect corresponding to the first therapy. The control parameter is set to a second value that differs from the first value. The system obtains glycemic control information resulting from the delivery of the second therapy using the second value of the control parameter and determines a second effect corresponding to the second therapy. The system can perform a comparative assessment and determine whether the second value for the control parameter results in a statistically significant improvement in glycemic control for the subject.Type: GrantFiled: March 5, 2021Date of Patent: September 5, 2023Assignee: BETA BIONICS, INC.Inventors: Edward R. Damiano, Firas H. El-Khatib
-
Patent number: 11698785Abstract: Systems and methods are disclosed herein for switching an application executing on an ambulatory medical device to a new application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system, download and install the application update, while a prior version of the application continues to run. The disclosed systems and methods can confirm successful installation of the application update on the ambulatory medical device and switch control of the ambulatory medical device from the prior version to the new version of the application without interrupting therapy provided to the subject.Type: GrantFiled: September 17, 2021Date of Patent: July 11, 2023Assignee: Beta Bionics, Inc.Inventors: Himanshu Patel, Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, John R. Costik, Justin P. Brown, Bryan Dale Knodel
-
Patent number: 11688501Abstract: Systems and methods are disclosed herein for managing access to therapy controls of an ambulatory medicament pump that provides therapy to a subject using safe access levels associated with the therapy controls. The therapy change controls may enable modification of the corresponding therapy control parameters. The disclosed systems and methods can determine the eligibility of a subject receiving therapy from the ambulatory medicament pump or a user of the ambulatory medicament pump, for a safe access level and provide access to the corresponding therapy change controls. The ambulatory medicament pump may provide access to the therapy change controls upon receiving an access signal. In some cases, the ambulatory medicament pump may receive a time-based passcode and provide access to the therapy change controls upon receiving a matching passcode from the user.Type: GrantFiled: March 1, 2022Date of Patent: June 27, 2023Assignee: Beta Bionics, Inc.Inventors: Michael J. Rosinko, Edward R. Damiano, Himanshu Patel, Firas H. El-Khatib, Robert James LeBourdais
-
Patent number: 11679201Abstract: A blood glucose control system can generate an indication of total carbohydrate therapy over a period during use by a subject. The system can be connected to a medicament pump configured to deliver insulin therapy, other types of medicament therapy, or a combination of medicament therapies to the subject. The system can determine an amount of a counter-regulatory agent to respond to an impending risk of hypoglycemia or an episode of hypoglycemia and determine a dose of carbohydrate therapy based at least in part on the amount of the counter-regulatory agent. The system can track determined doses of carbohydrate therapy to generate the indication of total carbohydrate therapy over the period.Type: GrantFiled: June 16, 2021Date of Patent: June 20, 2023Assignee: BETA BIONICS, INC.Inventors: Firas H. El-Khatib, Edward R. Damiano
-
Publication number: 20230166035Abstract: Automated glucose level control system that provide therapy to a subject, such as glucose control, are disclosed. The system generates dose control signals using control algorithms configured to autonomously determine doses of insulin to be infused into a subject. When the system determines that an initial dose control signal does not indicate health-appropriate therapy, the system can modify a manual therapy instruction and transmit an emergency dose control signal to the medicament pump. Disclosed systems and devices can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject. The system can generate a backup therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.Type: ApplicationFiled: August 5, 2022Publication date: June 1, 2023Inventors: Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano, David Chi-Wai Lim, Edward B. Raskin
-
Patent number: D1022185Type: GrantFiled: April 15, 2021Date of Patent: April 9, 2024Inventors: Bryan Dale Knodel, David Matthew Henderson, Edward R. Damiano, Michael J. Rosinko